What CHWs Need to Screen for Diabetes in the Field

Diabetes is the disease that hides in plain sight. It does not announce itself with a fever or a cough, and in most low- and middle-income countries the first sign is often a complication that arrives years too late. For the community health workers (CHWs) who form the front line of primary care in these settings, the operational problem is not treatment, it is detection. They are asked to flag a silent metabolic condition while carrying no laboratory, no cold chain, and frequently no reliable power. A workable community health worker diabetes screening process has to function inside those constraints, not in spite of them.

"Almost one in two adults aged 20 to 79 living with diabetes, around 239.7 million people, were unaware of their condition in 2021, and 87.5 percent of all undiagnosed cases were in low- and middle-income countries." - International Diabetes Federation, IDF Diabetes Atlas, 2021

That gap is the entire reason field screening matters. The people most likely to be undiagnosed live exactly where blood tests are hardest to deliver. The question for global health implementers is no longer whether CHWs should screen, but how to give them a repeatable workflow that sorts a population into who needs a confirmatory lab test and who does not.

Designing a community health worker diabetes screening workflow without a lab

The core principle of field-based community health worker diabetes screening is risk stratification, not diagnosis. A CHW does not need to confirm diabetes at the doorstep. They need to identify the subset of a population whose risk is high enough to justify the cost and travel of a confirmatory glucose or HbA1c test at a facility. That reframing changes what equipment is actually required.

The most validated tool for this job is a structured risk questionnaire. The Finnish Diabetes Risk Score (FINDRISC) uses eight questions covering age, body mass index, waist circumference, physical activity, diet, blood pressure medication use, history of high blood glucose, and family history. It requires no blood draw. When researchers took FINDRISC into vulnerable communities in Argentina in a 2023 feasibility study, 52.3 percent of participants scored at moderate or high risk (a score of 12 or above), and CHW involvement was identified as a key reason the screening was acceptable and could run at all.

A field workflow built around this logic has four stages a CHW can complete in a single household visit:

• Ask: administer the risk questionnaire, ideally on a phone that scores it automatically and removes arithmetic errors.
• Measure: capture the vital signs that sharpen risk, including blood pressure and, where possible, waist circumference and pulse.
• Sort: let the device classify the person as low, moderate, or high risk using a fixed threshold.
• Refer and record: flag high-risk individuals for confirmatory testing and log everyone so the cohort can be tracked over time.

What the CHW actually needs to carry

The deliberately short answer is a smartphone, a tape measure, and a referral pathway. Anthropometric data and a structured questionnaire do most of the stratification work. Where a CHW vital signs tool can capture blood pressure and heart rate from the same device, the screening becomes richer without adding a single piece of hardware, which matters because diabetes and hypertension cluster in the same patients.

Comparing field screening approaches

Implementers choosing a screening model are really choosing a trade-off between cost, throughput, and how much confirmation happens in the field. The table below compares the main options a mobile diabetes screening program in a low-resource setting will weigh.

Screening approach	Equipment required	Cost per screen	Field throughput	Best use case
Risk questionnaire only (FINDRISC-type)	Paper or smartphone	Very low	High	First-pass population stratification
Questionnaire plus smartphone vital signs	Smartphone, tape measure	Low	High	Combined diabetes and hypertension flagging
Capillary blood glucose at point of care	Glucometer, strips, lancets, sharps disposal	Medium to high	Medium	Confirmatory testing near a facility
HbA1c point-of-care device	Analyzer, cartridges, cold chain	High	Low	Diagnosis where supply chain allows
Facility laboratory referral	Lab infrastructure	High, plus travel cost to patient	Low	Definitive diagnosis after a positive flag

The pattern is consistent. The cheaper and more scalable approaches do not diagnose, they triage. The expensive approaches diagnose but collapse under field logistics. A well-designed program uses the top rows to decide who reaches the bottom rows, so that scarce confirmatory tests go to the people most likely to need them.

Industry Applications

National NCD programs

Ministries of health rolling out non-communicable disease (NCD) strategies increasingly want CHWs to screen for diabetes and hypertension in the same visit. A questionnaire-plus-vitals model fits the World Health Organization HEARTS and PEN frameworks, which were built for primary care settings without reliable laboratory access. The screening data also feeds population surveillance, which the IDF has repeatedly flagged as weak in exactly the regions with the most undiagnosed cases.

Donor-funded vertical programs

Programs originally built for HIV or tuberculosis are adding chronic disease screening to existing CHW visits because the marginal cost of one more questionnaire is close to zero. Field diabetes detection layered onto an established household visit schedule uses the same staff, the same routes, and the same devices, which is attractive to implementers under tightening budgets.

Mobile health platforms

For the platforms that equip CHWs, diabetes risk scoring is becoming a standard module rather than a custom build. Smartphone diagnostics in global health are converging on a model where one device runs the questionnaire, captures vitals, scores the risk, and queues the referral, all while working offline and syncing later.

Current research and evidence

The evidence base for CHW-led screening has matured. A 2024 systematic review protocol registered to examine CHW diabetes training across low- and middle-income countries reflects how much primary research now exists on the question, with studies catalogued through December 2023. The recurring finding is that CHWs improve screening reach when they are given a simple, structured tool and a clear referral pathway.

On the instrument itself, external validation continues to support questionnaire-based screening. A 2024 study of Peruvian hospital health care workers found that both the standard FINDRISC and a Latin American adaptation (LAFINDRISC) showed good discriminative capacity for undiagnosed dysglycemia, reinforcing that a non-invasive score can reliably separate higher-risk from lower-risk individuals before any blood is drawn. The Argentine feasibility work from 2023 adds the operational half of the story: the tool is not just statistically sound, it is acceptable to communities and deliverable by CHWs.

Two cautions run through this literature. First, a risk score is a sorting mechanism, not a diagnosis, and programs that treat a high score as a final answer misuse it. Second, screening without a functioning referral and treatment pathway generates flagged patients with nowhere to go, which erodes community trust. The measurement is the easy part. The system around it determines whether screening helps.

The future of field diabetes detection

The direction of travel is toward fewer dedicated devices and more capability concentrated in the phone a CHW already carries. Three shifts are visible. First, vital signs capture is moving from peripheral hardware toward camera- and sensor-based measurement, which removes consumables and calibration from the field equation. Second, risk algorithms are being localized, since a score validated in Finland needs adaptation to fit the body composition and risk profiles of South Asian or sub-Saharan African populations. Third, screening is becoming longitudinal rather than a one-time event, with repeat household visits building a record that catches people whose risk rises over time.

For mobile health platforms, the competitive question is shifting from "can you measure glucose in the field" to "can you stratify a whole population cheaply and route the right people to confirmation." That is a software and workflow problem as much as a hardware one, and it favors tools that work offline, score automatically, and integrate with existing CHW data systems.

Frequently asked questions

Can a community health worker diagnose diabetes without a blood test?

No, and they should not try. A CHW screens and stratifies risk using a structured questionnaire and basic vital signs. A diagnosis requires a confirmatory blood glucose or HbA1c test. The field workflow exists to identify who needs that confirmatory test, not to replace it.

What is the minimum a CHW needs to screen for diabetes risk?

At minimum, a validated risk questionnaire such as FINDRISC, a tape measure for waist circumference, and a clear referral pathway to a facility that can confirm and treat. A smartphone that scores the questionnaire and captures blood pressure makes the process faster and reduces errors.

Why focus screening on low- and middle-income countries?

Because that is where the undiagnosed cases concentrate. The IDF Diabetes Atlas 2021 reported that 87.5 percent of all undiagnosed diabetes cases globally are in low- and middle-income countries, with undiagnosed proportions above 50 percent in Africa, the Western Pacific, and South-East Asia.

How accurate are questionnaire-based risk scores?

Validation studies, including a 2024 Peruvian analysis, found that FINDRISC and its Latin American adaptation had good discriminative capacity for undiagnosed dysglycemia. They are reliable for sorting people into risk tiers, which is their intended purpose, but they are not a substitute for diagnostic blood testing.

Circadify is building toward this exact gap, developing a chronic disease screening module designed to let CHWs run diabetes and related risk stratification from a single smartphone without dedicated lab equipment. Mobile health platforms evaluating how this fits a field deployment can review deployment case studies and the global health work at circadify.com/blog.